Neuroprotectants targeting NMDA receptor signaling

Handbook of Neurotoxicity

Volumn 2, Issue , 2014, Pages 1381-1402

  Vetiska, Sandra M ^a   Tymianski, Michael ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971379661     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5836-4_168     Document Type: Chapter

References (167)

1. Aarsland, D., Ballard, C., Walker, Z., Bostrom, F., Alves, G., Kossakowski, K., Leroi, I., Pozo-Rodriguez, F., Minthon, L., & Londos, E. (2009). Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial. Lancet Neurology, 8, 613-618.
2. Aarts, M., Liu, Y., Liu, L., Besshoh, S., Arundine, M., Gurd, J. W., Wang, Y. T., Salter, M. W., & Tymianski, M. (2002). Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science, 298, 846-850.
3. Aarts, M., Iihara, K., Wei, W. L., Xiong, Z. G., Arundine, M., Cerwinski, W., MacDonald, J. F., & Tymianski, M. (2003a). A key role for TRPM7 channels in anoxic neuronal death. Cell, 115, 863-877.
4. Aarts, M. M., Arundine, M., & Tymianski, M. (2003b). Novel concepts in excitotoxic neurodegeneration after stroke. Expert Reviews in Molecular Medicine, 5, 1-22.
5. Arundine, M., & Tymianski, M. (2004). Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cellular and Molecular Life Sciences, 61, 657-668.
6. Arundine, M., Chopra, G. K., Wrong, A., Lei, S., Aarts, M. M., MacDonald, J. F., & Tymianski, M. (2003). Enhanced vulnerability to NMDA toxicity in sublethal traumatic neuronal injury in vitro. Journal of Neurotrauma, 20, 1377-1395.
7. Bach, A., Clausen, B. H., Moller, M., Vestergaard, B., Chi, C. N., Round, A., Sorensen, P. L., Nissen, K. B., Kastrup, J. S., Gajhede, M., Jemth, P., Kristensen, A. S., Lundstrom, P., Lambertsen, K. L., & Stromgaard, K. (2012). A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. Proceedings of the National Academy of Sciences of the United States of America, 109, 3317-3322.
8. Beister, A., Kraus, P., Kuhn, W., Dose, M., Weindl, A., & Gerlach, M. (2004). The N-methyl-D- aspartate antagonist memantine retards progression of Huntington's disease. Journal of Neural Transmission. Supplementum, 68, 117-122.
9. Berdichevsky, E., Riveros, N., Sanchez-Armass, S., & Orrego, F. (1983). Kainate, N- methylaspartate and other excitatory amino acids increase calcium influx into rat brain cortex cells in vitro. Neuroscience Letters, 36, 75-80.
10. Brenman, J. E., Chao, D. S., Gee, S. H., McGee, A. W., Craven, S. E., Santillano, D. R., Wu, Z., Huang, F., Xia, H., Peters, M. F., Froehner, S. C., & Bredt, D. S. (1996). Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alphal-syntrophin mediated by PDZ domains. Cell, 84, 757-767.
11. Bult, A., Zhao, F., Dirkx, R., Jr., Sharma, E., Lukacsi, E., Solimena, M., Naegele, J. R., & Lombroso, P. J. (1996). STEP61: A member of the family of brain-enriched PTPs is localized to the endoplasmic reticulum. The Journal of Neuroscience, 16, 7821-7831.
12. Cavara, N. A., & Hollmann, M. (2008). Shuffling the deck anew: How NR3 tweaks NMDA receptor function. Molecular Neurobiology, 38, 16-26.
13. Chatterton, J. E., Awobuluyi, M., Premkumar, L. S., Takahashi, H., Talantova, M., Shin, Y., Cui, J., Tu, S., Sevarino, K. A., Nakanishi, N., Tong, G., Lipton, S. A., & Zhang, D. (2002). Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature, 415, 793-798.
14. Chazot, P. L., & Stephenson, F. A. (1997). Molecular dissection of native mammalian forebrain NMDA receptors containing the NR1 C2 exon: Direct demonstration of NMDA receptors comprising NR1, NR2A, and NR2B subunits within the same complex. Journal of Neurochemistry, 69, 2138-2144.
15. Chazot, P. L., Coleman, S. K., Cik, M., & Stephenson, F. A. (1994). Molecular characterization of N-methyl-D-aspartate receptors expressed in mammalian cells yields evidence for the coexistence of three subunit types within a discrete receptor molecule. The Journal of Biological Chemistry, 269, 24403-24409.
16. Chen, M., Lu, T. J., Chen, X. J., Zhou, Y., Chen, Q., Feng, X. Y., Xu, L., Duan, W. H., & Xiong, Z. Q. (2008). Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke, 39, 3042-3048.
17. Cheung, H. H., Teves, L., Wallace, M. C., & Gurd, J. W. (2003). Inhibition of protein kinase C reduces ischemia-induced tyrosine phosphorylation of the N-methyl-D-aspartate receptor. Journal of Neurochemistry, 86, 1441-1449.
18. Cho, K. O., Hunt, C. A., & Kennedy, M. B. (1992). The rat brain postsynaptic density fraction contains a homolog of the Drosophila discs-large tumor suppressor protein. Neuron, 9, 929-942.
19. Choi, D. W. (1987). Ionic dependence of glutamate neurotoxicity. The Journal of Neuroscience, 7, 369-379.
20. Choi, D. W. (1988a). Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1, 623-634.
21. Choi, D. W. (1988b). Calcium-mediated neurotoxicity: Relationship to specific channel types and role in ischemic damage. Trends in Neurosciences, 11, 465-469.
22. Christopherson, K. S., Hillier, B. J., Lim, W. A., & Bredt, D. S. (1999). PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. The Journal of Biological Chemistry, 274, 27467-27473.
23. Cook, D. J., Teves, L., & Tymianski, M. (2012). Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature, 483, 213-217.
24. Craven, S. E., & Bredt, D. S. (1998). PDZ proteins organize synaptic signaling pathways. Cell, 93, 495-498.
25. Cui, H., Hayashi, A., Sun, H. S., Belmares, M. P., Cobey, C., Phan, T., Schweizer, J., Salter, M. W., Wang, Y. T., Tasker, R. A., Garman, D., Rabinowitz, J., Lu, P. S., & Tymianski, M. (2007). PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. The Journal of Neuroscience, 27, 9901-9915.
26. Cull-Candy, S. G. & Leszkiewicz, D. N. (2004). Role of distinct NMDA receptor subtypes at central synapses. Science STKE, 2004, re16.
27. Danysz, W., & Parsons, C. G. (2002). Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotoxicity Research, 4, 119-126.
28. Danysz, W., & Parsons, C. G. (2012). Alzheimer's disease, ß-amyloid, glutamate, NMDA receptors and memantine - Searching for the connections. British Journal of Pharmacology, 167, 324-352.
29. Das, S., Sasaki, Y. F., Rothe, T., Premkumar, L. S., Takasu, M., Crandall, J. E., Dikkes, P., Conner, D. A., Rayudu, P. V., Cheung, W., Chen, H. S. V., Lipton, S. A., & Nakanishi, N. (1998). Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature, 393, 377-381.
30. Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991). Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proceedings of the National Academy of Sciences of the United States of America, 88, 6368-6371.
31. Dawson, V. L., Dawson, T. M., Bartley, D. A., Uhl, G. R., & Snyder, S. H. (1993). Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. The Journal of Neuroscience, 13, 2651-2661.
32. DeRidder, M. N., Simon, M. J., Siman, R., Auberson, Y. P., Raghupathi, R., & Meaney, D. F. (2006). Traumatic mechanical injury to the hippocampus in vitro causes regional caspase-3 and calpain activation that is influenced by NMDA receptor subunit composition. Neurobiology of Disease, 22, 165-176.
33. Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999). The glutamate receptor ion channels. Pharmacological Reviews, 51, 7-61.
34. D'Mello, R., Marchand, F., Pezet, S., McMahon, S. B., & Dickenson, A. H. (2011). Perturbing PSD-95 interactions with NR2B-subtype receptors attenuates spinal nociceptive plasticity and neuropathic pain. Molecular Therapy, 19, 1780-1792.
35. Dykstra, C. M., Ratnam, M., & Gurd, J. W. (2009). Neuroprotection after status epilepticus by targeting protein interactions with postsynaptic density protein 95. Journal ofNeuropathology and Experimental Neurology, 68, 823-831.
36. Feng, W., & Zhang, M. (2009). Organization and dynamics of PDZ-domain-related supramodules in the postsynaptic density. Nature Reviews Neuroscience, 10, 87-99.
37. Florio, S. K., Loh, C., Huang, S. M., Iwamaye, A. E., Kitto, K. F., Fowler, K. W., Treiberg, J. A., Hayflick, J. S., Walker, J. M., Fairbanks, C. A., & Lai, Y. (2009). Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. British Journal of Pharmacology, 158, 494-506.
38. Furukawa, H., & Gouaux, E. (2003). Mechanisms of activation, inhibition and specificity: Crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO Journal, 22, 2873-2885.
39. Furukawa, H., Singh, S. K., Mancusso, R., & Gouaux, E. (2005). Subunit arrangement and function in NMDA receptors. Nature, 438, 185-192.
40. Gardoni, F. (2008). MAGUK proteins: New targets for pharmacological intervention in the glutamatergic synapse. European Journal of Pharmacology, 585, 147-152.
41. Ghosh, A., & Greenberg, M. E. (1995). Calcium signaling in neurons: Molecular mechanisms and cellular consequences. Science, 268, 239-247.
42. Gingrich, J. R., Pelkey, K. A., Fam, S. R., Huang, Y., Petralia, R. S., Wenthold, R. J., & Salter, M. W. (2004). Unique domain anchoring of Src to synaptic NMDA receptors via the mitochondrial protein NADH dehydrogenase subunit 2. Proceedings of the National Academy of Sciences of the United States of America, 101, 6237-6242.
43. Gladding, C. M., & Raymond, L. A. (2011). Mechanisms underlying NMDA receptor synaptic/ extrasynaptic distribution and function. Molecular and Cellular Neurosciences, 48, 308-320.
44. Gladstone, D. J., Black, S. E., & Hakim, A. M. (2002). Toward wisdom from failure: Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke, 33, 2123-2136.
45. Gouix, E., Leveille, F., Nicole, O., Melon, C., Had-Aissouni, L., & Buisson, A. (2009). Reverse glial glutamate uptake triggers neuronal cell death through extrasynaptic NMDA receptor activation. Molecular and Cellular Neurosciences, 40, 463-473.
46. Groe, L., Bard, L., & Choquet, D. (2009). Surface trafficking of N-methyl-D-aspartate receptors: Physiological and pathological perspectives. Neuroscience, 158, 4-18.
47. Groc, L., Heine, M., Cousins, S. L., Stephenson, F. A., Lounis, B., Cognet, L., & Choquet, D. (2006). NMDA receptor surface mobility depends on NR2A-2B subunits. Proceedings of the National Academy of Sciences of the United States of America, 103, 18769-18774.
48. Hardingham, G. E., & Bading, H. (2003). The Yin and Yang of NMDA receptor signaling. Trends in Neurosciences, 26, 81-89.
49. Hardingham, G. E., & Bading, H. (2010). Synaptic versus extrasynaptic NMDA receptor signaling: Implications for neurodegenerative disorders. Nature Reviews Neuroscience, 11, 682-696.
50. Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature Neuroscience, 5, 405-414.
51. Harris, A. Z., & Pettit, D. L. (2007). Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices. The Journal of Physiology, 584, 509-519.
52. Herrmann, N., Li, A., & Lanctot, K. (2011). Memantine in dementia: A review of the current evidence. Expert Opinion on Pharmacotherapy, 12, 787-800.
53. Hill, M. D. M., Martin, R. H., Mikulis, D., Wong, J. H., Silver, F. L., terBrugge, K. G., Milot, G., Clarke, W. M., MacDonald, R. L., Kelly, M. E., Boulton, M., Fleetwood, I., MacDougall, C., Gunnarsson, T., Chow, M., Lum, C., Dodd, R., Poublanc, J., Krings, T., Demchuk, A. M., Goyal, M., Anderson, R., Bishop, J., Garman, D., & Tymianski, M. (2012). Safety and efficacy of NA-1 for neuroprotection in iatrogenic stroke after endovascular aneurysm repair: A randomized controlled trial. Lancet Neurology, 12, 70225-70229.
54. Hollmann, M., & Heinemann, S. (1994). Cloned glutamate receptors. Annual Review of Neuroscience, 17, 31-108.
55. Hossain, M. I., Kamaruddin, M. A., & Cheng, H. C. (2012). Aberrant regulation and function of Src family tyrosine kinases: Their potential contributions to glutamate-induced neurotoxicity. Clinical and Experimental Pharmacology and Physiology, 39, 684-691.
56. Hoyte, L., Barber, P. A., Buchan, A. M., & Hill, M. D. (2004). The rise and fall of NMDA antagonists for ischemic stroke. Current Molecular Medicine, 4, 131-136.
57. Ikonomidou, C., & Turski, L. (2002). Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurology, 1, 383-386.
58. Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wolfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., Eckert, A., Staufenbiel, M., Hardeman, E., & Gotz, J. (2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell, 142, 387-397.
59. Jiang, X., Mu, D., Biran, V., Faustino, J., Chang, S., Rincon, C. M., Sheldon, A., & Ferriero, D. M. (2008). Activated Src kinases interact with the N-methyl-D-aspartate receptor after neonatal brain ischemia. Annals of Neurology, 63, 632-641.
60. Johnson, J. W., & Ascher, P. (1987). Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature, 325, 529-531.
61. Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008). NMDA receptors in clinical neurology: Excitatory times ahead. Lancet Neurology, 7, 742-755.
62. Kaufman, A. M., Milnerwood, A. J., Sepers, M. D., Coquinco, A., She, K., Wang, L., Lee, H., Craig, A. M., Cynader, M., & Raymond, L. A. (2012). Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. The Journal of Neuroscience, 32, 3992-4003.
63. Kennedy, M. B. (1997). The postsynaptic density at glutamatergic synapses. Trends in Neurosciences, 20, 264-268.
64. Kleckner, N. W., & Dingledine, R. (1988). Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science, 241, 835-837.
65. Kohr, G. (2006). NMDA receptor function: Subunit composition versus spatial distribution. Cell and Tissue Research, 326, 439-446.
66. Kornau, H. C., Schenker, L. T., Kennedy, M. B., & Seeburg, P. H. (1995). Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science, 269, 1737-1740.
67. Lai, T. W., & Wang, Y. T. (2010). Fashioning drugs for stroke. Nature Medicine, 16, 1376-1378.
68. Lai, T. W., Shyu, W. C., & Wang, Y. T. (2011). Stroke intervention pathways: NMDA receptors and beyond. Trends in Molecular Medicine, 17, 266-275.
69. Lau, A., & Tymianski, M. (2010). Glutamate receptors, neurotoxicity and neurodegeneration. Pfliigers Archiv, 460, 525-542.
70. Lerma, J., Zukin, R. S., & Bennett, M. V. (1990). Glycine decreases desensitization of N-methyl-D- aspartate (NMDA) receptors expressed in Xenopus oocytes and is required for NMDA responses. Proceedings of the National Academy of Sciences of the United States of America, 87, 2354-2358.
71. Leveille, F., El Gaamouch, F., Gouix, E., Lecocq, M., Lobner, D., Nicole, O., & Buisson, A. (2008). Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. The FASEB Journal, 22, 4258-4271.
72. Leveille, F., Papadia, S., Fricker, M., Bell, K. F., Soriano, F. X., Martel, M. A., Puddifoot, C., Habel, M., Wyllie, D. J., Ikonomidou, C., Tolkovsky, A. M., & Hardingham, G. E. (2010). Suppression of the intrinsic apoptosis pathway by synaptic activity. The Journal of Neuroscience, 30, 2623-2635.
73. Liang, S., Pong, D., Gonzales, C., Chen, Y., Ling, H. P., Mark, R. J., Boschelli, F., Boschelli, D. H., Ye, F., Barrios Sosa, A. C., Mansour, T. S., Frost, P., Wood, A., Pangalos, M. N., & Zaleska, M. M. (2009). Neuroprotective profile of novel Src kinase inhibitors in rodent models of cerebral ischemia. The Journal of Pharmacology and Experimental Therapeutics, 331, 827-835.
74. Lipton, S. A., & Rosenberg, P. A. (1994). Excitatory amino acids as a final common pathway for neurologic disorders. The New England Journal of Medicine, 330, 613-622.
75. Liu, Y., Wong, T. P., Aarts, M., Rooyakkers, A., Liu, L., Lai, T. W., Wu, D. C., Lu, J., Tymianski, M., Craig, A. M., & Wang, Y. T. (2007). NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. The Journal of Neuroscience, 27, 2846-2857.
76. Liu, X. J., Gingrich, J. R., Vargas-Caballero, M., Dong, Y. N., Sengar, A., Beggs, S., Wang, S. H., Ding, H. K., Frankland, P. W., & Salter, M. W. (2008). Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex. Nature Medicine, 14, 1325-1332.
77. Liu, S. B., Zhang, N., Guo, Y. Y., Zhao, R., Shi, T. Y., Feng, S. F., Wang, S. Q., Yang, Q., Li, X. Q., Wu, Y. M., Ma, L., Hou, Y., Xiong, L. Z., Zhang, W., & Zhao, M. G. (2012). G- protein-coupled receptor 30 mediates rapid neuroprotective effects of estrogen via depression of NR2B-containing NMDA receptors. The Journal of Neuroscience, 32, 4887-4900.
78. Lucas, D. R., & Newhouse, J. P. (1957). The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Archives of Ophthalmology, 58, 193-201.
79. MacDermott, A. B., Mayer, M. L., Westbrook, G. L., Smith, S. J., & Barker, J. L. (1986). NMDA- receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature, 321, 519-522.
80. 2+ signaling, cell death and stroke. Trends in Neurosciences, 29, 75-81.
81. Martel, M. A., Soriano, F. X., Baxter, P., Rickman, C., Duncan, R., Wyllie, D. J., & Hardingham, G. E. (2009). Inhibiting pro-death NMDA receptor signaling dependent on the NR2 PDZ ligand may not affect synaptic function or synaptic NMDA receptor signaling to gene expression. Channels (Austin, Tex.), 3, 12-15.
82. Martel, M. A., Ryan, T. J., Bell, K. F. S., Fowler, J. H., McMahon, A., Al-Mubarak, B., Komiyama, N. H., Horsburgh, K., Kind, P. C., Grant, S. G. N., & Wyllie, D. J. A. (2012). The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron, 74, 543-556.
83. McBain, C. J., & Mayer, M. L. (1994). N-methyl-D-aspartic acid receptor structure and function. Physiological Reviews, 74, 723-760.
84. McShane, R., Areosa, S. A., & Minakaran, N. (2006). Memantine for dementia. Cochrane Database of Systematic Reviews, 2, 1-42.
85. Milnerwood, A. J., Gladding, C. M., Pouladi, M. A., Kaufman, A. M., Hines, R. M., Boyd, J. D., Ko, R. W. Y., Vasuta, O. C., Graham, R. K., Hayden, M. R., Murphy, T. H., & Raymond, L. A. (2010). Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron, 65, 178-190.
86. Moon, I. S., Apperson, M. L., & Kennedy, M. B. (1994). The major tyrosine-phosphorylated protein in the postsynaptic density fraction is N-methyl-D-aspartate receptor subunit 2B. Proceedings of the National Academy of Sciences of the United States of America, 91, 3954-3958.
87. Morris, G. F., Bullock, R., Marshall, S. B., Marmarou, A., Maas, A., & Marshall, L. F. (1999). Failure of the competitive N-Methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two Phase III clinical trials. The Selfotel Investigators. Journal of Neurosurgery, 91, 737-743.
88. Moussa, R. C., Ikeda-Douglas, C. J., Thakur, V., Milgram, N. W., & Gurd, J. W. (2001). Seizure activity results in increased tyrosine phosphorylation of the N-methyl-D-aspartate receptor in the hippocampus. Brain Research. Molecular Brain Research, 95, 36-47.
89. Muir, K. W. (2006). Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Current Opinion in Pharmacology, 6, 53-60.
90. Nakanishi, S. (1992). Molecular diversity of glutamate receptors and implications for brain function. Science, 258, 597-603.
91. Niethammer, M., Kim, E., & Sheng, M. (1996). Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. The Journal of Neuroscience, 16, 2157-2163.
92. Nilius, B., & Owsianik, G. (2011). The transient receptor potential family of ion channels. Genome Biology, 12, 218-228.
93. Ning, K., Pei, L., Liao, M., Liu, B., Zhang, Y., Jiang, W., Mielke, J. G., Li, L., Chen, Y., El-Hayek, Y. H., Fehlings, M. G., Zhang, X., Liu, F., Eubanks, J., & Qan, Q. (2004). Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN. The Journal of Neuroscience, 24, 4052-4060.
94. Ohnishi, H., Murata, Y., Okazawa, H., & Matozaki, T. (2011). Src family kinases: modulators of neurotransmitter receptor function and behavior. Trends in Neurosciences, 34, 629-637.
95. Okabe, S. (2007). Molecular anatomy of the postsynaptic density. Molecular and Cellular Neurosciences, 34, 503-518.
96. Okamoto, S., Pouladi, M. A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D. E., Zaidi, R., Clemente, A., Kaul, M., Graham, R. K., Zhang, D., Chen, H. S. V., Tong, G., Hayden, M. R., & Lipton, S. A. (2009). Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nature Medicine, 15, 1407-1413.
97. Olney, J. W. (1969). Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science, 164, 719-721.
98. Olney, J. W., & de Gubareff, T. (1978). The fate of synaptic receptors in the kainate-lesioned striatum. Brain Research, 140, 340-343.
99. Ondo, W. G., Mejia, N. I., & Hunter, C. B. (2007). A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism & Related Disorders, 13, 453-454.
100. Pachernegg, S., Strutz-Seebohm, N., & Hollmann, M. (2012). GluN3 subunit-containing NMDA receptors: Not just one-trick ponies. Trends in Neurosciences, 35, 240-249.
101. Paoletti, P., & Neyton, J. (2007). NMDA receptor subunits: function and pharmacology. Current Opinion in Pharmacology, 7, 39-47.
102. Parsons, C. G., Danysz, W., & Quack, G. (1999). Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology, 38, 735-767.
103. Pelkey, K. A., Askalan, R., Paul, S., Kalia, L. V., Nguyen, T. H., Pitcher, G. M., Salter, M. W., & Lombroso, P. J. (2002). Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. Neuron, 34, 127-138.
104. Pivovarova, N. B., & Andrews, S. B. (2010). Calcium-dependent mitochondrial function and dysfunction in neurons. The FEBS Journal, 277, 3622-3636.
105. Prybylowski, K., & Wenthold, R. J. (2004). N-Methyl-D-aspartate receptors: subunit assembly and trafficking to the synapse. The Journal of Biological Chemistry, 279, 9673-9676.
106. Radi, R., Beckman, J. S., Bush, K. M., & Freeman, B. A. (1991a). Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. The Journal of Biological Chemistry, 266, 4244-4250.
107. Radi, R., Beckman, J. S., Bush, K. M., & Freeman, B. A. (1991b). Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Archives of Biochemistry and Biophysics, 288, 481-487.
108. Rammes, G., Danysz, W., & Parsons, C. G. (2008). Pharmacodynamics of memantine: An update. Current Neuropharmacology, 6, 55-78.
109. Rao, V. L., Dogan, A., Todd, K. G., Bowen, K. K., & Dempsey, R. J. (2001). Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Research, 911, 96-100.
110. Regan, R. F., & Choi, D. W. (1991). Glutamate neurotoxicity in spinal cord cell culture. Neuroscience, 43, 585-591.
111. Roesler, R., Quevedo, J., & Schroder, N. (2003). Is it time to conclude that NMDA antagonists have failed? Lancet Neurology, 2, 13.
112. Rojas, J. C., Saavedra, J. A., & Gonzalez-Lima, F. (2008). Neuroprotective effects of memantine in a mouse model of retinal degeneration induced by rotenone. Brain Research, 1215, 208-217.
113. Rostas, J. A., Brent, V. A., Voss, K., Errington, M. L., Bliss, T. V., & Gurd, J. W. (1996). Enhanced tyrosine phosphorylation of the 2B subunit of the N-methyl-D-aspartate receptor in long-term potentiation. Proceedings of the National Academy of Sciences of the United States of America, 93, 10452-10456.
114. Ryan, T. J., Emes, R. D., Grant, S. G., & Komiyama, N. H. (2008). Evolution of NMDA receptor cytoplasmic interaction domains: Implications for organisation of synaptic signaling complexes. BMC Neuroscience, 9, 6.
115. Salter, M. W. (1998). Src, N-methyl-D-aspartate (NMDA) receptors, and synaptic plasticity. Biochemical Pharmacology, 56, 789-798.
116. Salter, M. W., & Kalia, L. V. (2004). Src kinases: A hub for NMDA receptor regulation. Nature Reviews Neuroscience, 5, 317-328.
117. Salter, M. W., & Pitcher, G. M. (2012). Dysregulated Src upregulation of NMDA receptor activity: A common link in chronic pain and schizophrenia. The FEBS Journal, 279, 2-11.
118. Sanna, P. P., Berton, F., Cammalleri, M., Tallent, M. K., Siggins, G. R., Bloom, F. E., & Francesconi, W. (2000). A role for Src kinase in spontaneous epileptiform activity in the CA3 region of the hippocampus. Proceedings of the National Academy of Sciences of the United States of America, 97, 8653-8657.
119. Sanz-Clemente, A., Nicoll, R. A., & Roche, K. W. (2012). Diversity in NMDA receptor composition: Many regulators, many consequences. Neuroscientist, 19, 62-75.
120. Sattler, R., & Tymianski, M. (2000). Molecular mechanisms of calcium-dependent excitotoxicity. Journal of Molecular Medicine (Berlin), 78, 3-13.
121. Sattler, R., Xiong, Z., Lu, W. Y., Hafner, M., MacDonald, J. F., & Tymianski, M. (1999). Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science, 284, 1845-1848.
122. Sattler, R., Xiong, Z., Lu, W. Y., MacDonald, J. F., & Tymianski, M. (2000). Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. The Journal of Neuroscience, 20, 22-33.
123. Schifitto, G., Navia, B. A., Yiannoutsos, C. T., Marra, C. M., Chang, L., Ernst, T., Jarvik, J. G., Miller, E. N., Ginger, E. J., Ellis, R. J., Kolson, D. L., Simpson, D., Nath, A., Berger, J., Shriver, S. L., Millar, L. L., Colquhoun, D., Lenkinski, R., Gonzalez, R. G., Lipton, S. A., & Adult AIDS Clinical Trial Group (ACTG) 301, 700 Teams, HIV MRS Consortium. (2007). Memantine and HIV-associated cognitive impairment: A neuropsychological and proton magnetic resonance spectroscopy study. AIDS, 21, 1877-1886.
124. Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999). In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science, 285, 1569-1572.
125. Shan, Y., Liu, B., Li, L., Chang, N., Li, L., Wang, H., Wang, D., Feng, H., Cheung, C., Liao, M., Cui, T., Sugita, S., & Wan, Q. (2009). Regulation of PINK1 by NR2B-containing NMDA receptors in ischemic neuronal injury. Journal of Neurochemistry, 111, 1149-1160.
126. Sharma, E., Zhao, F., Bult, A., & Lombroso, P. J. (1995). Identification of two alternatively spliced transcripts of STEP: A subfamily of brain-enriched protein tyrosine phosphatases. Brain Research. Molecular Brain Research, 32, 87-93.
127. Sheng, M. (2001). Molecular organization of the postsynaptic specialization. Proceedings of the National Academy of Sciences of the United States of America, 98, 7058-7061.
128. Sheng, M., & Sala, C. (2001). PDZ domains and the organization of supramolecular complexes. Annual Review of Neuroscience, 24, 1-29.
129. Song, C., Zhang, Y., Parsons, C. G., & Liu, Y. F. (2003). Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. The Journal of Biological Chemistry, 278, 33364-33369.
130. Soriano, F. X., & Hardingham, G. E. (2007). Compartmentalized NMDA receptor signaling to survival and death. The Journal of Physiology, 584, 381-387.
131. Soriano, F. X., Martel, M. A., Papadia, S., Vaslin, A., Baxter, P., Rickman, C., Forder, J., Tymianski, M., Duncan, R., Aarts, M., Clarke, P. G. H., Wyllie, D. J. A., & Hardingham, G. E. (2008). Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. The Journal of Neuroscience, 28, 10696-10710.
132. Stieg, P. E., Sathi, S., Warach, S., Le, D. A., & Lipton, S. A. (1999). Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. European Journal of Pharmacology, 375, 115-120.
133. Sugihara, H., Moriyoshi, K., Ishii, T., Masu, M., & Nakanishi, S. (1992). Structures and properties of seven isoforms of the NMDA receptor generated by alternative splicing. Biochemical and Biophysical Research Communications, 185, 826-832.
134. Sun, H. S., Doucette, T. A., Liu, Y., Fang, Y., Teves, L., Aarts, M., Ryan, C. L., Bernard, P. B., Lau, A., Forder, J. P., Salter, M. W., Wang, Y. T., Tasker, A., & Tymianski, M. (2008). Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke, 39, 2544-2553.
135. Sun, H. S., Jackson, M. F., Martin, L. J., Jansen, K., Teves, L., Cui, H., Kiyonaka, S., Mori, Y., Jones, M., Forder, J. P., Golde, T. E., Orser, B. A., MacDonald, J. F., & Tymianski, M. (2009). Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia. Nature Neuroscience, 12, 1300-1307.
136. Szydlowska, K., & Tymianski, M. (2010). Calcium, ischemia and excitotoxicity. Cell Calcium, 47, 122-129.
137. Taghibiglou, C., Martin, H. G., Lai, T. W., Cho, T., Prasad, S., Kojic, L., Lu, J., Liu, Y., Lo, E., Zhang, S., Wu, J. Z. Z., Li, Y. P., Wen, Y. H., Imm, J. H., Cynader, M. S., & Wang, Y. T. (2009). Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries. Nature Medicine, 15, 1399-1406.
138. Tao, F., Tao, Y. X., Gonzalez, J. A., Fang, M., Mao, P., & Johns, R. A. (2001). Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats. Neuroreport, 12, 3251-3255.
139. Tao, F., Tao, Y. X., Mao, P., & Johns, R. A. (2003). Role of postsynaptic density protein-95 in the maintenance of peripheral nerve injury-induced neuropathic pain in rats. Neuroscience, 117, 731-739.
140. Tao, F., Su, Q., & Johns, R. A. (2008). Cell-permeable peptide Tat-PSD-95 PDZ2 inhibits chronic inflammatory pain behaviors in mice. Molecular Therapy, 16, 1776-1782.
141. Terasaki, Y., Sasaki, T., Yagita, Y., Okazaki, S., Sugiyama, Y., Oyama, N., Omura-Matsuoka, E., Sakoda, S., & Kitagawa, K. (2010). Activation of NR2A receptors induces ischemic tolerance through CREB signaling. Journal of Cerebral Blood Flow and Metabolism, 30, 1441-1449.
142. Tezuka, T., Umemori, H., Akiyama, T., Nakanishi, S., & Yamamoto, T. (1999). PSD-95 promotes Fyn-mediated tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit NR2A. Proceedings of the National Academy of Sciences of the United States of America, 96, 435-440.
143. Thomas, S. J., & Grossberg, G. T. (2009). Memantine: A review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clinical Interventions in Aging, 4, 367-377.
144. Thomas, C. G., Miller, A. J., & Westbrook, G. L. (2006). Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. Journal ofNeurophysiology, 95, 1727-1734.
145. Tovar, K. R., & Westbrook, G. L. (1999). The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. The Journal of Neuroscience, 19, 4180-4188.
146. Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010). Glutamate receptor ion channels: Structure, regulation, and function. Pharmacological Reviews, 62, 405-496.
147. Tu, W., Xu, X., Peng, L., Zhong, X., Zhang, W., Soundarapandian, M. M., Balel, C., Wang, M., Jia, N., Zhang, W., Lew, F., Chan, S. L., Chen, Y., & Lu, Y. (2010). DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell, 140, 222-234.
148. Tymianski, M. (2011). Emerging mechanisms of disrupted cellular signaling in brain ischemia. Nature Neuroscience, 14, 1369-1373.
149. Tymianski, M., Charlton, M. P., Carlen, P. L., & Tator, C. H. (1993). Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. The Journal ofNeuroscience, 13, 2085-2104.
150. Vanhoutte, P., & Bading, H. (2003). Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signaling and BDNF gene regulation. Current Opinion in Neurobiology, 13, 366-371.
151. Verpelli, C., Schmeisser, M. J., Sala, C., & Boeckers, T. M. (2012). Scaffold proteins at the postsynaptic density. Advances in Experimental Medicine and Biology, 970, 29-61.
152. Volbracht, C., van Beek, J., Zhu, C., Blomgren, K., & Leist, M. (2006). Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. The European Journal of Neuroscience, 23, 2611-2622.
153. Wang, Y. T., & Salter, M. W. (1994). Regulation of NMDA receptors by tyrosine kinases and phosphatases. Nature, 369, 233-235.
154. Wang, C. X., & Shuaib, A. (2005). NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Current Drug Targets. CNS and Neurological Disorders, 4, 143-151.
155. Wilhelmus, M. M., Nijland, P. G., Drukarch, B., de Vries, H. E., & van Horssen, J. (2012). Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegeneration and neuroinflammatory disorders. Free Radical Biology & Medicine, 53, 983-992.
156. Wood, P. L., & Hawkinson, J. E. (1997). N-methyl-D-aspartate antagonists for stroke and head trauma. Expert Opinion on Investigational Drugs, 6, 389-397.
157. Xia, P., Chen, H. S., Zhang, D., & Lipton, S. A. (2010). Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. The Journal of Neuroscience, 30, 11246-11250.
158. Xie, Y. F., MacDonald, J. F., & Jackson, M. F. (2010). TRPM2, calcium and neurodegenerative diseases. International Journal of Physiology, Pathophysiology and Pharmacology, 2, 95-103.
159. Xu, J., Kurup, P., Zhang, Y., Goebel-Goody, S. M., Wu, P. H., Hawasli, A. H., Baum, M. L., Bibb, J. A., & Lombroso, P. J. (2009). Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. The Journal of Neuroscience, 29, 9330-9343.
160. Zhao, Y., Navia, B. A., Marra, C. M., Singer, E. J., Chang, L., Berger, J., Ellis, R. J., Kolson, D. L., Simpson, D., Miller, E. N., Lipton, S. A., Evans, S. R., Schifitto, G., & The Adult AIDS Clinical Trial Group (ACTG) 301 Team. (2010). Memantine for AIDS dementia complex: Open-label report of ACTG 301. HIV Clinical Trials, 11, 59-67.
161. Zheng, F., Gingrich, M. B., Treynelis, S. F., & Conn, P. J. (1998). Tyrosine kinase potentiates NMDA receptor currents by reducing tonic zinc inhibition. Nature Neuroscience, 1, 185-191.
162. Zheng, C. Y., Seabold, G. K., Horak, M., & Petralia, R. S. (2011). MAGUKs, synaptic development, and synaptic plasticity. The Neuroscientist, 17, 493-512.
163. Zhou, M., & Baudry, M. (2006). Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. The Journal of Neuroscience, 26, 2956-2963.
164. Zhou, L., Li, F., Xu, H. B., Luo, C. X., Wu, H. Y., Zhu, M. M., Lu, W., Ji, X., Zhou, Q. G., & Zhu, D. Y. (2010). Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nature Medicine, 16, 1439-1443.
165. Ziff, E. B. (1997). Enlightening the postsynaptic density. Neuron, 19, 1163-1174.
166. Zou, J., & Crews, F. (2006). CREB and NF-kappaB transcription factors regulate sensitivity to excitotoxic and oxidative stress induced neuronal cell death. Cellular and Molecular Neurobiology, 26, 385-405.
167. Zukin, R. S., & Bennett, M. V. (1995). Alternatively spliced isoforms of the NMDARI receptor subunit. Trends in Neurosciences, 18, 306-313.